| Title |
AMPD1: a novel therapeutic target for reversing insulin resistance
|
|---|---|
| Published in |
BMC Endocrine Disorders, December 2014
|
| DOI | 10.1186/1472-6823-14-96 |
| Pubmed ID | |
| Authors |
Jidong Cheng, Hiroko Morisaki, Keiko Toyama, Naomi Sugimoto, Takuya Shintani, Andreas Tandelilin, Tetsuaki Hirase, Edward W Holmes, Takayuki Morisaki |
| Abstract |
Insulin resistance is one of the hallmark manifestations of obesity and Type II diabetes and reversal of this pathogenic abnormality is an attractive target for new therapies for Type II diabetes. A recent report that metformin, a drug known to reverse insulin resistance, demonstrated in vitro the metformin can inhibit AMP deaminase (AMPD) activity. Skeletal muscle is one of the primary organs contributing to insulin resistance and that the AMPD1 gene is selectively expressed at high levels in skeletal muscle. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 20% |
| Researcher | 6 | 17% |
| Student > Ph. D. Student | 5 | 14% |
| Other | 3 | 9% |
| Student > Bachelor | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 11 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 26% |
| Biochemistry, Genetics and Molecular Biology | 5 | 14% |
| Immunology and Microbiology | 3 | 9% |
| Agricultural and Biological Sciences | 2 | 6% |
| Psychology | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 12 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2021.
All research outputs
#18,386,678
of 22,774,233 outputs
Outputs from BMC Endocrine Disorders
#495
of 746 outputs
Outputs of similar age
#256,551
of 354,430 outputs
Outputs of similar age from BMC Endocrine Disorders
#8
of 9 outputs
Altmetric has tracked 22,774,233 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 746 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,430 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.